Literature DB >> 101186

Treatment of childhood epilepsy with dipropylacetic acid (DPA).

I Lagenstein, H J Sternowsky, E Blaschke, M Rothe, R Fehr.   

Abstract

Dipropylacetate (DPA) was used in the treatment of different types of epilepsy in 112 children aged 1--20 years, with a mean age of 9.2 years, for a period of 19.8 months, ranging from 1 to 49 months. Of this group, 64 children were therapy-resistant to other antiepileptic medications prior to the introduction of DPA; 31 were treated for the first time with an antiepileptic drug, which was DPA; 44 were treated with DPA alone; and 68 had one or more additional antiepileptic medication. The following results were found while DPA was administered in a relatively high dosage with a mean of 48 mg/kg body weight/day and ranging from 7 to 125 mg/kg/day. 1. Statistically, the results are significantly better in primary generalized epilepsy than in partial or in secondary generalized epilepsy. 2. Ninety-two percent of 51 patients who had absences were treated successfully. The same applies to 87% of 30 patients with primary generalized grand mal with spike wave, to all four patients who had impulsive petit mal, and to 47% of the 15 patients who had centrencephalic myoclonic-astatic petit mal. 3. Positive effect of DPA in partial epilepsy and secondary generalized epilepsy was seen only if the EEG pattern was 'centrencephalic' besides focal changes. During therapy with DPA, five patients with pure focal EEG showed an increase in seizure frequency, which demonstrated complete therapeutic failure. 4. Centrencephalic seizure activity (irregular spike wave, 3/s spike wave, and more than 3.5/s spike wave) were treated successfully (P less than 0.001). Focal changes or focal sharp wave with tendency to spread or generalization were treated unsucessfully.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 101186     DOI: 10.1007/bf00344123

Source DB:  PubMed          Journal:  Arch Psychiatr Nervenkr (1970)


  25 in total

1.  [Clinical observations on the effect of dipropylacetic acid in epileptic and behavioral manifestations].

Authors:  F Mairlot
Journal:  Rev Neuropsychiatr Infant       Date:  1970-03

2.  Clinical and electroencephalographical classification of epileptic seizures.

Authors:  H Gastaut
Journal:  Epilepsia       Date:  1970-03       Impact factor: 5.864

3.  [Treatment of atypical absences with a combination of succinimide and dipropylacetate (author's transl)].

Authors:  H Schneble
Journal:  Dtsch Med Wochenschr       Date:  1975-07-25       Impact factor: 0.628

4.  [Anticonvulsive therapy using dipropylacetate in children].

Authors:  C Förster
Journal:  Munch Med Wochenschr       Date:  1972-03-03

5.  Centrencephalic myoclonic-astatic petit mal. Clinical and genetic investigation.

Authors:  H Doose; H Gerken; R Leonhardt; E Völzke; C Völz
Journal:  Neuropadiatrie       Date:  1970-08

6.  Clinical trials of anti-epileptic drugs.

Authors:  H Meinardi
Journal:  Psychiatr Neurol Neurochir       Date:  1971 Mar-Apr

7.  Experiences on the use of dipropylacetate in the treatment of childhood epilepsy.

Authors:  M Sillanpää; M Donner
Journal:  Acta Paediatr Scand       Date:  1976-03

8.  [Clinical evaluation of sodium dipropylacetate (DPA), a new anti-epileptic drug].

Authors:  Y Aoki; T Wada; T Takahashi; K Mitsutsuka; S Toraiwa
Journal:  No To Shinkei       Date:  1969-11

9.  [First clinical results of a new anti-epileptic: sodium di-n-propyl acetate (DPA) specialized under the marketed name, Depakine].

Authors:  D de Biolley; L Sorel
Journal:  Acta Neurol Psychiatr Belg       Date:  1969-11

10.  Childhood epileptic encephalopathy with diffuse slow spike-waves (otherwise known as "petit mal variant") or Lennox syndrome.

Authors:  H Gastaut; J Roger; R Soulayrol; C A Tassinari; H Régis; C Dravet; R Bernard; N Pinsard; M Saint-Jean
Journal:  Epilepsia       Date:  1966-06       Impact factor: 6.740

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.